Homology Medicines (NASDAQ:FIXX) Upgraded by Zacks Investment Research to Buy

0
51

Homology Medicines stock has undergone multiple analysts rating changes in the recent past.  Homology Medicines Upgraded by Zacks Investment Research on 10/18/2021. In a note to investors, the firm issued a new rating of Buy. The analysts previously had rating of Hold.

Shares of Homology Medicines traded down -$0.16 on Monday, reaching $6.04. 568792 shares of the stock traded hands, compared to its average volume of 535486. Shares of Homology Medicines were trading at $6.04 on Monday. The firm’s 50 day moving average is $7.20 and its 200 day moving average is $8.41.Homology Medicines has a 12 month low of $5.98 and a 12 month high of $15.24. While on yearly highs and lows, Homology Medicines’s today has traded high as $6.28 and has touched $5.98 on the downward trend. See More Analyst Rating at: RATING

Homology Medicines Earnings and What to expect: 

Homology Medicines last posted its earnings results on August 12th, 2021. The reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.04. The firm earned $2.19 million during the quarter, compared to the consensus estimate of $0.63 million. Homology Medicines has generated ($2.80) earnings per share over the last year (($1.80) diluted earnings per share). Earnings for Homology Medicines are expected to decrease in the coming year, from ($1.82) to ($2.44) per share. Homology Medicines has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, November 8th, 2021 based off prior year’s report dates.

Earnings for Homology Medicines are expected to decrease in the coming year, from ($1.82) to ($2.44) per share. The P/E ratio of Homology Medicines is -3.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Homology Medicines is -3.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Homology Medicines has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Homology Medicines (NASDAQ:FIXX) Moving Average Technical Analysis

5 day Moving Average is $6.24 And 5 day price change is -$0.45 (-6.93%)  with average volume for 5 day average is 615,840. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $7.26 and 20 day price change is -$2.20 (-26.70%) and average 20 day moving volume is 450,490. 50 day moving average is $7.20  and 50 day price change is -$0.80 ( -11.70%)  and with average volume for 50 days is : 479,176. 200 day moving average is $8.41  and 200 day price change is -$5.25 (-46.50%)  and with average volume for 200 days is : 536,895.

Other owners latest trading in Homology Medicines :

  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 27,197 which equates to market value of $0.20M and appx 0.00% owners of Homology Medicines
  • On 8/25/2021 shares held by Marshall Wace LLP were 406,401 which equates to market value of $2.95M and appx 0.00% owners of Homology Medicines
  • On 8/23/2021 shares held by Morgan Stanley were 224,866 which equates to market value of $1.63M and appx 0.00% owners of Homology Medicines
  • In total Institutional ownership equates to Institutional Ownership Percentage: 57.39% for Homology Medicines

See More Analyst Rating at: RATING